Califf Confident Public Trust In US FDA Will Be Rebuilt
Commissioner nominee strikes an optimistic note as former FDA heads raise concerns about the decrease in agency credibility during the pandemic.
You may also be interested in...
The FDA’s principal deputy commissioner wonders how the agency will work with ARPA-H to help get its projects to patients and the health care system given its other responsibilities.
The US FDA's comment came in response to a question about whether accelerated approval encourages sponsors to conduct lower-quality studies to enter the market.
Scott Gottlieb says that some meetings should remain in-person, but with virtual options proven effective, the FDA could offer more opportunities to talk to sponsors.